BeyondSpring (BYSI) Net Cash Flow (2016 - 2026)
BeyondSpring (BYSI) posted Net Cash Flow of -$3.0 million for Q1 2026, up 65.96% sequentially from -$8.7 million in Q4 2025, and down 240.31% YoY from $2.1 million in Q1 2025.
BeyondSpring (BYSI) Net Cash Flow (2016 - 2026) Analysis & Trends
BeyondSpring has reported Net Cash Flow for 9 years, with the latest figure at -$3.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 240.31% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (down 435.49% YoY) and the FY2025 annual result came in at -$4.0 million, down 140.36% from the prior year.
- Net Cash Flow climbed to -$3.0 million in Q1 2026 per BYSI's latest filing, from -$8.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $14.6 million in Q3 2024 and troughed at -$8.7 million in Q4 2025.
- A 3-year average of -$1.3 million and a median of -$3.0 million in 2026 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 171.24% in 2025, then tumbled 240.31% in 2026.
- Over 3 years, Net Cash Flow stood at -$7.0 million in 2024, then decreased by 24.18% to -$8.7 million in 2025, then surged by 65.96% to -$3.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.0 million, -$8.7 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.85 Mn |
| Jun 30, 2026 | -3.85 Mn |
| Mar 31, 2026 | -2.96 Mn |
| Mar 31, 2026 | -2.96 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Sep 30, 2025 | -2.42 Mn |
| Sep 30, 2025 | -2.42 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | -6.99 Mn |
| Dec 31, 2024 | -6.99 Mn |
| Sep 30, 2024 | 14.57 Mn |
| Sep 30, 2024 | 14.57 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |